Intravesical therapy for bladder cancer in the pandemic of Covid-19
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu dopisy
PubMed
32356225
PubMed Central
PMC7191133
DOI
10.1007/s00345-020-03218-8
PII: 10.1007/s00345-020-03218-8
Knihovny.cz E-zdroje
- MeSH
- adjuvancia imunologická aplikace a dávkování MeSH
- aplikace intravezikální MeSH
- BCG vakcína aplikace a dávkování MeSH
- COVID-19 * MeSH
- lidé MeSH
- nádory močového měchýře farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- dopisy MeSH
- Názvy látek
- adjuvancia imunologická MeSH
- BCG vakcína MeSH
Department of Surgery S H Ho Urology Centre The Chinese University of Hong Kong Hong Kong China
Department of Urology Charles University Prague Czech Republic
Department of Urology Hanover Medical School Hannover Germany
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology Spital Thurgau AG Frauenfeld Switzerland
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Sorbonne University GRC n°5 Predicitive onco uro AP HP Hôpital Pitié Salpêtrière 75013 Paris France
Zobrazit více v PubMed
World Health Organization (2020) WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed 19 Mar 2020.
Oke J, Heneghan C (2020) Global Covid-19 case fatality rates. https://www.cebm.net/global-covid-19-case-fatality-rates/. Accessed 19 Mar 2020.
Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–795. doi: 10.1016/j.eururo.2018.09.001. PubMed DOI
Gudaru K, Blanco LT, Castellani D, Santamaria HT, Pelayo-Nieto M, Linden-Castro E, Wroclawski ML, Bellote MC, Inarritu JM, da Silva RD, Gauhar V, Adwin Z, Teoh JY. Connecting the urological community : the #UroSoMe experience. J Endolumin Endourol. 2019;2(2):320–e329. doi: 10.22374/jeleu.v2i2.44. DOI
Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008;53(4):709–719. doi: 10.1016/j.eururo.2008.01.015. PubMed DOI PMC
Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001;21(1B):765–769. PubMed
Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Hoeltl W, Turkeri L, Marreaud S, Collette S, Oosterlinck W. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–472. doi: 10.1016/j.eururo.2012.10.039. PubMed DOI
Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decock M, Pirson M, Jurion F, Palfliet K, Denis O, Simon J, Schulman CC. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol. 2000;37(4):470–477. doi: 10.1159/000020170. PubMed DOI
Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004;63(4):682–686. doi: 10.1016/j.urology.2003.11.049. PubMed DOI
Hegarty PK, Kamat A, Zafirakis H, Dinardo A (2020) BCG vaccination may be protective against Covid-19. https://www.researchgate.net/publication/340224580_BCG_vaccination_may_be_protective_against_Covid-19/citations. Accessed 5 Apr 2020.
